Rebecca Sumner

Rebecca L. Sumner is a clinical researcher specialising in experimental psychopharmacology with a primary focus on low‑dose (microdosing) administration of lysergic acid diethylamide (LSD). Her recent work centres on rigorous human‑subject investigations — including a home‑administered randomised controlled trial examining acute mood effects of microdosed LSD, controlled assessments of post‑dose sleep changes, an open‑label trial in people with major depressive disorder, and multimodal studies probing creativity and neurophysiological plasticity.

Sumner's contributions bridge clinical trial methods and mechanistic neuroscience: she has been involved in studies that combine behavioural and subjective outcome measures with thalamo‑cortical modelling and markers of synaptic plasticity (long‑term potentiation) to better characterise how repeated microdoses affect cognition, mood and sleep. Her work emphasises controlled, reproducible protocols for microdosing research and seeks to clarify both therapeutic potential and mechanistic underpinnings of sub‑psychedelic LSD dosing regimens.